Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C21H20N2O5
CAS Number:
Molecular Weight:
380.39
UNSPSC Code:
41106300
NACRES:
NA.77
Product Name
Varespladib, ≥98% (HPLC)
SMILES string
[Na+].[n]2(c3c(c(ccc3)OCC(=O)[O-])c(c2CC)C(=O)C(=O)N)Cc1ccccc1
InChI
1S/C21H20N2O5.Na/c1-2-14-19(20(26)21(22)27)18-15(9-6-10-16(18)28-12-17(24)25)23(14)11-13-7-4-3-5-8-13;/h3-10H,2,11-12H2,1H3,(H2,22,27)(H,24,25);/q;+1/p-1
InChI key
XZZUHXILQXLTGV-UHFFFAOYSA-M
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
−20°C
Quality Level
Related Categories
Application
Varespladib has been used as a secretory phospholipase A (sPLA2) inhibitor:
- to test its effect on the human astrocytes subjected to psychosine-induced toxicity
- to test its neutralization functionality on the black snake species P. colletti venom
- in combination with snake venom metalloproteinases (SVMP)-inhibitor, marimastat to test its protective functionality on envenoming by vipers
Biochem/physiol Actions
Varespladib is a potent and selective inhibitor of secretory phospholipase A2 (sPLA2).
Varespladib is a potent and selective inhibitor of secretory phospholipase A2 (sPLA2). The compound Varespladib inhibits both human and mouse sPLA2 group IIA, V, and X enzymes at low nM concentrations.
Varespladib is effective against viper and elapid venoms and is used in snakebite therapy. It is reported to interact with the hydrophobic channel of the PLA2-like toxin in in vitro structural studies. It blocks inflammatory cascades related to the sPLA2.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Guilherme H M Salvador et al.
Scientific reports, 9(1), 17203-17203 (2019-11-22)
The World Health Organization recently listed snakebite envenoming as a Neglected Tropical Disease, proposing strategies to significantly reduce the global burden of this complex pathology by 2030. In this context, effective adjuvant treatments to complement conventional antivenom therapy based on
Christina N Zdenek et al.
Toxicology letters, 330, 176-184 (2020-05-23)
Venoms from Pseudechis species (Australian black snakes) within the Elapidae family are rich in anticoagulant PLA2 toxins, with the exception of one species (P. porphyriacus) that possesses procoagulant mutated forms of the clotting enzyme Factor Xa. Previously the mechanism of
Laura-Oana Albulescu et al.
Nature communications, 11(1), 6094-6094 (2020-12-17)
Snakebite is a medical emergency causing high mortality and morbidity in rural tropical communities that typically experience delayed access to unaffordable therapeutics. Viperid snakes are responsible for the majority of envenomings, but extensive interspecific variation in venom composition dictates that
Cedric Misslin et al.
PloS one, 12(11), e0187217-e0187217 (2017-11-03)
Krabbe disease is a fatal rare inherited lipid storage disorder affecting 1:100,000 births. This illness is caused by mutations in the galc gene encoding for the enzyme galactosylceramidase (GALC). Dysfunction of GALC has been linked to the toxic build-up of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service